Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Background: TRC102 inhibits base excision repair by binding abasic sites and preventing AP endonuclease processing; it potentiates the activity of alkylating agents, including temozolomide, in murine models. In published xenograft studies, TRC102 enhanced the antitumor effect of temozolomide regardl...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Coyne, Geraldine O'Sullivan, Kummar, Shivaani, Meehan, Robert S., Do, Khanh, Collins, Jerry M., Anderson, Larry, Ishii, Kazusa, Takebe, Naoko, Zlott, Jennifer, Juwara, Lamin, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Rubinstein, Larry, Voth, Andrea Regier, Lozier, Jay, Dull, Angie B., Wilsker, Deborah, Hinoue, Toshinori, Laird, Peter W., Ferry-Galow, Katherine V., Kinders, Robert J., Parchment, Ralph E., Doroshow, James H., Chen, Alice P.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2020
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646836/
https://ncbi.nlm.nih.gov/pubmed/33216844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27784
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια